Topiramate is used for weight loss, though not in the way you might expect. The FDA has never approved topiramate on its own as a weight loss medication. It’s approved for epilepsy and migraine prevention. However, it is a key ingredient in Qsymia, an FDA-approved weight loss drug that combines topiramate with phentermine. Doctors also frequently prescribe topiramate by itself, off-label, specifically because weight loss is a well-documented and consistent side effect.
How Topiramate Causes Weight Loss
Topiramate was originally designed to control seizures, but patients in early trials kept losing weight. The drug works on multiple brain pathways at once. It enhances the activity of GABA, a brain chemical that calms neural signaling, and it blocks certain receptors involved in excitatory signaling. The combined effect appears to reduce appetite and change how the brain responds to food cues. Research in animal models also suggests topiramate improves how the brain processes insulin and leptin, two hormones that regulate hunger and energy balance. The exact reason it causes weight loss isn’t fully mapped out, which is part of why it remains an off-label option rather than a standalone approved treatment.
How Much Weight You Can Expect to Lose
On topiramate alone, weight loss is moderate but meaningful. In a randomized controlled trial of people with obesity and type 2 diabetes, those taking topiramate lost an average of 6 kg (about 13 pounds) over 16 weeks, representing roughly 5.8% of their starting body weight. The placebo group lost only 2.5 kg over the same period. A broader analysis of multiple studies found average losses of about 5.34 kg when topiramate was combined with lifestyle changes like diet and exercise.
Most people lose between 5% and 7% of their starting body weight after about six months. Higher doses tend to produce more weight loss, but also more side effects. Weight loss typically becomes noticeable within the first few months and continues gradually. If you don’t see results by 16 weeks, the medication may not be effective for you at that dose.
The FDA-Approved Combination: Qsymia
The FDA approved Qsymia in July 2012 for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol. In 2022, the approval expanded to include adolescents aged 12 and older with a BMI at or above the 95th percentile for their age. The drug pairs a low dose of phentermine (a stimulant that suppresses appetite) with extended-release topiramate. The two medications target different appetite pathways, and using lower doses of each is thought to produce a synergistic effect while keeping side effects manageable.
In a study of patients with obesity and heart failure, the generic combination of phentermine and topiramate produced an average weight loss of 5.6 kg at 6 months and 11 kg at 12 months. Patients who stayed on therapy for at least two years achieved an average 11% reduction in total body weight. Generic versions of both drugs are available individually, sometimes costing as little as $20 per month combined, which makes this approach significantly cheaper than branded weight loss medications.
How It’s Typically Prescribed Off-Label
When doctors prescribe topiramate alone for weight management, the approach is gradual. A common starting dose is 25 mg taken at bedtime. The dose is increased by 25 mg at monthly visits, but only if weight loss has stalled and the patient is tolerating the medication well. Most prescribers cap the dose at 100 mg per day, occasionally going up to 150 mg. Taking it at night helps because one of its main side effects, drowsiness, works in your favor while you sleep.
This slow titration matters. Many of topiramate’s side effects are dose-dependent, and ramping up too quickly makes them worse. Your doctor will likely check blood work before starting, including kidney and liver function and bicarbonate levels, since topiramate can affect all three. Ongoing monitoring typically includes quarterly weigh-ins and annual blood panels.
Side Effects to Know About
Topiramate’s side effect profile is the main reason some people stop taking it. The most common complaints are tingling or prickling sensations in the hands and feet, trouble concentrating, memory problems, and difficulty finding the right word during conversation. Some people describe a general mental fogginess or slowing down, which has earned topiramate the nickname “dopamax” among patients. These cognitive effects tend to be more pronounced at higher doses and often improve over time, but for some people they’re a dealbreaker.
Kidney stones are a recognized risk. Published clinical trials report an incidence of about 1.5% of patients, though some studies in specific populations have found higher rates with long-term use. Staying well hydrated is important while taking this medication.
Pregnancy Risks Are Serious
Topiramate poses significant risks during pregnancy, and this is one of the most important considerations for anyone of childbearing age. Birth defects, particularly cleft lip and cleft palate, occur in 4 to 9 out of every 100 babies born to women taking topiramate during pregnancy, compared to 1 to 3 per 100 in the general population. About 18 out of every 100 exposed newborns are born smaller and lighter than expected, compared to 5 per 100 in unexposed pregnancies. The European Medicines Agency has issued specific recommendations to avoid topiramate exposure during pregnancy, and reliable contraception is considered essential for women taking this drug.
How Topiramate Compares to Newer Options
Topiramate produces more modest weight loss than the newer GLP-1 medications like semaglutide, which can produce 15% or greater reductions in body weight. Where topiramate holds an advantage is cost and accessibility. Generic topiramate is widely available and inexpensive, while GLP-1 medications can cost over $1,000 per month and have faced ongoing supply shortages. For people who can’t access or tolerate newer options, topiramate, either alone or combined with phentermine, remains a practical and evidence-backed choice. The generic phentermine and topiramate combination, in particular, was well tolerated in studies with no major cardiovascular events and favorable reductions in blood pressure.